Hainan Richsun Pharmaceutical

Hainan Richsun Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, and manufacturing of chemical drugs. Headquartered in Haikou, the company focuses on therapeutic areas such as anti-infectives, cardiovascular diseases, and digestive system disorders. Its commercial portfolio includes a wide range of generic antibiotics, including cephalosporins like Cefixime and Cefdinir. Richsun operates state-of-the-art, GMP-certified production facilities that support both active pharmaceutical ingredient (API) synthesis and finished dosage forms. Beyond its generic business, the company is actively investing in innovative drug R&D, with candidates like the novel anti-infective RS-1801 in its pipeline. The company serves as a key player in the regional pharmaceutical industry of Hainan Province and targets the broader Chinese healthcare market.